http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2060507-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 |
| filingDate | 1990-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a76864f29a27d14f51da4245af57bb9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72ff28cf9b52b4305b199da542bf81da |
| publicationDate | 1996-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2060507-C |
| titleOfInvention | Factor xa based anticoagulant compositions |
| abstract | An anticoagulant composition containing an effective amount of factor Xa having the active serine site inactivated that functions rapidly and effectively in vivo to suppress coagulation. In a preferred embodiment Factor Xa, a serine esterase that forms a complex vith Factor Va, Ca + +, and phospholipid to catalyze prothrombin activation, is first inactivated with an active site inhibitor, such as dansyl-glu-gly-arg-chloromethyl ketone, to form inactivated factor Xa. In another embodiment, Factor Xa is expressed from a gene sequence wherein the portion encoding the active serine region is modified. The inactivated protein re-tains the ability to bind to endogenous factot Va in vivo, and has a half-life of approximately ten hours. Administration of inac-tive factor Xa to the blood of a patient without in the formation of inactive factor Xa-Va complexes in vivo, thereby inhibiting coagulation. |
| priorityDate | 1989-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 141.